XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases…
News
GEMMABio raises $34m to advance gene therapy programmes
Novo gets the green light for once-daily haemophilia drug following setbacks
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment
FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea
SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
